Display options
Cite
Moyes KW, Davis A, Hoglund V, et al. Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. Oncoimmunology. 2018;7(11):e1507668doi: 10.1080/2162402X.2018.1507668.
Moyes, K. W., Davis, A., Hoglund, V., Haberthur, K., Lieberman, N. A., Kreuser, S. A., Deutsch, G. H., Franco, S., Locke, D., Carleton, M. O., Gilbertson, D. G., Simmons, R., Winter, C., Silber, J., Gonzalez-Cuyar, L. F., Ellenbogen, R. G., & Crane, C. A. (2018). Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. Oncoimmunology, 7(11), e1507668. https://doi.org/10.1080/2162402X.2018.1507668
Moyes, Kara W, et al. "Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma." Oncoimmunology vol. 7,11 (2018): e1507668. doi: https://doi.org/10.1080/2162402X.2018.1507668
Moyes KW, Davis A, Hoglund V, Haberthur K, Lieberman NA, Kreuser SA, Deutsch GH, Franco S, Locke D, Carleton MO, Gilbertson DG, Simmons R, Winter C, Silber J, Gonzalez-Cuyar LF, Ellenbogen RG, Crane CA. Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. Oncoimmunology. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668. eCollection 2018. PMID: 30377570; PMCID: PMC6204983.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668. eCollection 2018.

Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma.

Oncoimmunology

Kara W Moyes, Amira Davis, Virginia Hoglund, Kristen Haberthur, Nicole Ap Lieberman, Shannon A Kreuser, Gail H Deutsch, Stephanie Franco, Darren Locke, Michael O Carleton, Debra G Gilbertson, Randi Simmons, Conrad Winter, John Silber, Luis F Gonzalez-Cuyar, Richard G Ellenbogen, Courtney A Crane

Affiliations

  1. Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA.
  2. Department of Pathology, Seattle Children's Hospital, Seattle, WA, USA.
  3. Bristol-Myers Squibb, Princeton, NJ, USA.
  4. Oncoresponse, Seattle, WA, USA.
  5. Department of Neurological Surgery, University of Washington, Seattle WA, USA.
  6. Department of Pathology, University of Washington, Seattle, WA, USA.

PMID: 30377570 PMCID: PMC6204983 DOI: 10.1080/2162402X.2018.1507668

Abstract

Efforts to reduce immunosuppression in the solid tumor microenvironment by blocking the recruitment or polarization of tumor associated macrophages (TAM), or myeloid derived suppressor cells (MDSCs), have gained momentum in recent years. Expanding our knowledge of the immune cell types, cytokines, or recruitment factors that are associated with high-grade disease, both within the tumor and in circulation, is critical to identifying novel targets for immunotherapy. Furthermore, a better understanding of how therapeutic regimens, such as Dexamethasone (Dex), chemotherapy, and radiation, impact these factors will facilitate the design of therapies that can be targeted to the appropriate populations and retain efficacy when administered in combination with standard of care regimens. Here we perform quantitative analysis of tissue microarrays made of samples taken from grades I-III astrocytoma and glioblastoma (GBM, grade IV astrocytoma) to evaluate infiltration of myeloid markers CD163, CD68, CD33, and S100A9. Serum, flow cytometric, and Nanostring analysis allowed us to further elucidate the impact of Dex treatment on systemic biomarkers, circulating cells, and functional markers within tumor tissue. We found that common myeloid markers were elevated in Dex-treated grade I astrocytoma and GBM compared to non-neoplastic brain tissue and grade II-III astrocytomas. Cell frequencies in these samples differed significantly from those in Dex-naïve patients in a pattern that depended on tumor grade. In contrast, observed changes in serum chemokines or circulating monocytes were independent of disease state and were due to Dex treatment alone. Furthermore, these changes seen in blood were often not reflected within the tumor tissue.

Keywords: Dexamethasone; Glioblastoma; cancer immunology; immunotherapy; tumor associated macrophage

References

  1. Acta Neuropathol. 1997 May;93(5):518-27 - PubMed
  2. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  3. Blood. 1997 Oct 1;90(7):2541-8 - PubMed
  4. Clin Cancer Res. 2012 Nov 15;18(22):6110-21 - PubMed
  5. Oncogene. 2008 Jan 7;27(2):190-9 - PubMed
  6. Eur J Immunol. 2014 Jun;44(6):1814-22 - PubMed
  7. J Clin Invest. 2015 Sep;125(9):3356-64 - PubMed
  8. J Leukoc Biol. 2013 Apr;93(4):633-7 - PubMed
  9. Acta Neuropathol. 1999 Oct;98(4):349-54 - PubMed
  10. Immunity. 2011 Jan 28;34(1):50-60 - PubMed
  11. Clin Cancer Res. 2013 Jul 15;19(14):3776-86 - PubMed
  12. Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5 - PubMed
  13. Neuro Oncol. 2010 Jul;12(7):631-44 - PubMed
  14. Nat Cell Biol. 2015 Feb;17(2):170-82 - PubMed
  15. Cancer Res. 2014 Sep 15;74(18):5057-69 - PubMed
  16. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8 - PubMed
  17. Nat Rev Immunol. 2017 Apr;17(4):233-247 - PubMed
  18. J Biol Chem. 2011 Nov 4;286(44):38703-13 - PubMed
  19. Cancer Cell. 2017 Jul 10;32(1):42-56.e6 - PubMed
  20. Haematologica. 2018 Mar;103(3):395-405 - PubMed
  21. J Leukoc Biol. 2008 Sep;84(3):644-50 - PubMed
  22. Brain Behav Immun. 2016 May;54:86-94 - PubMed
  23. J Clin Invest. 2016 Jul 1;126(7):2610-20 - PubMed
  24. Eur J Endocrinol. 2017 May;176(5):R205-R216 - PubMed
  25. Nat Commun. 2016 Jul 06;7:12150 - PubMed
  26. Mol Med Rep. 2015 Apr;11(4):2397-406 - PubMed
  27. Onco Targets Ther. 2016 Apr 27;9:2535-45 - PubMed
  28. Nature. 2015 Mar 19;519(7543):366-9 - PubMed
  29. Acta Neuropathol Commun. 2017 Jan 10;5(1):4 - PubMed
  30. Cell. 1989 Feb 10;56(3):335-44 - PubMed
  31. Hum Gene Ther. 2017 Feb;28(2):200-215 - PubMed
  32. Nat Med. 2007 Jan;13(1):84-8 - PubMed
  33. Neuro Oncol. 2015 Feb;17(2):266-73 - PubMed
  34. J Immunol Res. 2016;2016:6031486 - PubMed
  35. J Exp Med. 2008 Jun 9;205(6):1261-8 - PubMed
  36. Acta Neuropathol. 2014 Sep;128(3):347-62 - PubMed
  37. Int J Cancer. 2017 Oct 1;141(7):1434-1444 - PubMed
  38. Genes Dev. 2017 Apr 15;31(8):774-786 - PubMed
  39. Int J Oncol. 2009 Jun;34(6):1621-7 - PubMed
  40. Oncotarget. 2016 Dec 6;7(49):80521-80542 - PubMed
  41. J Neurooncol. 2011 Aug;104(1):83-92 - PubMed
  42. J Immunol. 2008 Oct 15;181(8):5791-802 - PubMed
  43. Trends Immunol. 2016 Mar;37(3):208-220 - PubMed
  44. JCI Insight. 2016;1(2): - PubMed
  45. Anticancer Res. 1997 Sep-Oct;17(5A):3217-24 - PubMed
  46. Neuro Oncol. 2016 Jun;18(6):797-806 - PubMed
  47. J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 - PubMed
  48. Neuro Oncol. 2011 Jun;13(6):591-9 - PubMed
  49. J Clin Invest. 2007 Apr;117(4):902-9 - PubMed
  50. Clin Cancer Res. 2017 Dec 1;23(23):7333-7339 - PubMed
  51. Oncoimmunology. 2017 Aug 8;6(11):e1358839 - PubMed
  52. J Immunol. 1989 Nov 15;143(10):3222-9 - PubMed
  53. Clin Cancer Res. 2017 Jul 15;23(14):3575-3584 - PubMed
  54. Neuro Oncol. 2012 May;14(5):584-95 - PubMed
  55. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  56. Cancer Res. 2016 Oct 1;76(19):5671-5682 - PubMed
  57. Brain. 2016 May;139(Pt 5):1458-71 - PubMed
  58. J Leukoc Biol. 2000 Jan;67(1):97-103 - PubMed
  59. Neurology. 2016 Jun 14;86(24):2226-34 - PubMed
  60. Gynecol Oncol. 2017 Mar;144(3):480-485 - PubMed
  61. Nat Rev Clin Oncol. 2017 Jul;14(7):399-416 - PubMed
  62. J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9 - PubMed
  63. Oncotarget. 2014 Mar 30;5(6):1452-7 - PubMed
  64. J Immunol. 1999 Sep 15;163(6):3524-9 - PubMed
  65. Cancer Immunol Immunother. 2016 Mar;65(3):283-91 - PubMed
  66. Immunology. 2012 Jun;136(2):176-83 - PubMed
  67. Oncotarget. 2017 Jul 25;8(30):49470-49483 - PubMed
  68. Sci Rep. 2018 Jan 15;8(1):777 - PubMed
  69. J Neurooncol. 2012 May;108(1):187-93 - PubMed
  70. Neuro Oncol. 2017 May 1;19(5):648-659 - PubMed
  71. PLoS One. 2015 Mar 23;10(3):e0121546 - PubMed
  72. Genome Biol. 2017 Dec 20;18(1):234 - PubMed
  73. J Clin Oncol. 2015 Sep 1;33(25):2812-4 - PubMed
  74. Nat Neurosci. 2016 Jan;19(1):20-7 - PubMed

Publication Types